Original language | English (US) |
---|---|
Article number | 607298 |
Journal | Frontiers in Oncology |
Volume | 10 |
DOIs | |
State | Published - Oct 23 2020 |
Funding
We are grateful to all authors that contributed to this e-book. Funding. RdL was supported by AUA Research Scholar Award and Prostate Cancer Foundation Young Investigator Award; QC by DoD (W81XWH1710357 and W81XWH1910563), ACS (RSG1519201), NIH/NCI (R01CA208257 and Prostate SPORE P50CA180995), and Northwestern Univ. Polsky Urologic Cancer Institute; H-ML by NIH Prostate Cancer SPORE (P50CA97186), DoD Prostate Cancer Biorepository Network, and Institute of Prostate Cancer Research. RdL was supported by AUA Research Scholar Award and Prostate Cancer Foundation Young Investigator Award; QC by DoD (W81XWH1710357 and W81XWH1910563), ACS (RSG1519201), NIH/NCI (R01CA208257 and Prostate SPORE P50CA180995), and Northwestern Univ. Polsky Urologic Cancer Institute; H-ML by NIH Prostate Cancer SPORE (P50CA97186), DoD Prostate Cancer Biorepository Network, and Institute of Prostate Cancer Research.
Keywords
- androgen deprivation therapy (ADT)
- castration-resistant prostate cancer
- neuroendocrine prostate cancer
- new therapy
- treatment resistance
ASJC Scopus subject areas
- Oncology
- Cancer Research